Pipeline
Our Commitment to Continuous Improvement
| Asset | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | |
|---|---|---|---|---|---|---|---|
|
Sales |
EDx700™
Exosomal Hsp70 Liquid Biopsy
|
Marketing Approval & Commercialization EU |
Pre-Approval USA |
||||
|
R&D |
EDx900™
Circulating Tumor Cell Isolation
|
Development USA/EU |
Development USA/EU |
Development USA/ EU |
|
File IND |
Phase 1 |
|
R&D |
EDx700™ / PSA Combination Test
|
Development USA/EU |
Development USA/EU |
